{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:50:03Z","timestamp":1765954203004,"version":"3.48.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data on the effects of sacubitril\/valsartan combined with dapagliflozin in non-diabetic patients with advanced chronic kidney disease (CKD) are limited. In this study, we evaluated the efficacy and safety of sacubitril\/valsartan plus dapagliflozin in non-diabetic patients with advanced CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, prospective cohort study was conducted in non-diabetic patients with advanced CKD who had not yet initiated renal replacement therapy. Group A included 65 patients who received combined sacubitril\/valsartan and dapagliflozin therapy, while Group B consisted of 59 patients treated with sacubitril\/valsartan alone. Estimated glomerular filtration rate (eGFR), proteinuria, blood pressure and serum potassium levels were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline eGFR was 36.35(31.00, 46.47) and 40.01(30.12, 45.86) mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      in the Group A and Group B, respectively. There was significant difference in eGFR between the two groups at month 6 [30.92(25.38, 35.38) vs. 25.42(21.58, 30.27)mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001]. The difference in the change in eGFR between the two groups was statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Compared with sacubitril\/valsartan alone, the combination of sacubitril\/valsartan and dapagliflozin provided an additional significant reduction in blood pressure, attenuated the decline in eGFR, reduced proteinuria, and lowered the risk of hyperkalemia (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In non-diabetic patients suffering from advanced CKD, treatment with sacubitril\/valsartan combined with dapagliflozin effectively controlled blood pressure, reduced proteinuria, slowed the progression of renal dysfunction, and did not increase the risk of adverse events, indicating a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1681260","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:45:36Z","timestamp":1765953936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of sacubitril\/valsartan combined with dapagliflozin in non-diabetic patients with advanced chronic kidney disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Huifang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003136","article-title":"Epidemiology and outcomes of hypertensive crisis in patients with chronic kidney disease: a nationwide analysis","volume":"40","author":"Pothuru","year":"2022","journal-title":"J Hypertens"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL-cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"sfae100","DOI":"10.1093\/ckj\/sfae100","article-title":"Dapagliflozin treatment in non-diabetic chronic kidney disease across different albuminuria levels (OPTIMISE-CKD)","volume":"17","author":"Svensson","year":"2024","journal-title":"Clin Kidney J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/147323001103900624","article-title":"Assessment of the CKD-EPI equation to estimate glomerular filtration rate in adults from a Chinese CKD population","volume":"39","author":"Liao","year":"2011","journal-title":"J Int Med Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","article-title":"The proportion of missing data should not be used to guide decisions on multiple imputation","volume":"110","author":"Madley-Dowd","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1119","article-title":"Hypertension management in patients with chronic kidney disease","volume":"18","author":"Hebert","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2015.1","article-title":"Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction","volume":"38","author":"Ito","year":"2015","journal-title":"Hypertens Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00982.x","article-title":"Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy","volume":"66","author":"Benigni","year":"2004","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.10.432","article-title":"Angiotensin receptor neprilysin inhibitor use and blood pressure lowering in patients with heart failure with reduced ejection fraction across the spectrum of kidney function","volume":"29","author":"Gjyriqi","year":"2023","journal-title":"J Card Fail"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomized, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1574693","article-title":"Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med (Lausanne)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1681260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:45:38Z","timestamp":1765953938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1681260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":19,"alternative-id":["10.3389\/fendo.2025.1681260"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1681260","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1681260"}}